IntroductionImplantable cardioverter defibrillators register various types of arrhythmias. Thus they can be exploited to better identify patients with atrial fibrillation episodes and increase the proportion of patients who may benefit from implementation of pharmacological prophylaxis of thromboembolic events, most of which it turns out are asymptomatic.Material and methodsAssessment of the frequency, symptoms and predisposing factors for the occurrence of atrial fibrillation episodes in patients with implanted ICD (implantable cardioverter defibrillator) and CRT-D (cardiac resynchronisation therapy with defibrillator) based on the analysis of intracardiac electrocardiograms (IEGM) records. The study included 174 consecutive outpatient cases with heart failure, sinus rhythm and Implanted Cardioverter Defibrillator and Cardiac Resynchronisation Therapy with Defibrillator. Control visits with analysis of IEGM records occurred every three months. During mean follow-up of 20 months, 901 visits were carried out. 147 patients had at least one year of follow-up.ResultsAtrial fibrillation episodes in the study group occurred in 54 (31.0%) of patients and 71.4% were asymptomatic. Predisposing factors were: history of paroxysmal atrial fibrillation (37.0% vs 13.3%, p ˂ 0.001), atrioventricular conduction abnormalities (42.6% vs. 20.0%, p = 0.002), intraventricular conduction abnormalities (59.3% vs 40.8%, p = 0.02) and more severe mitral regurgitation (7.4% vs 0.8%, p = 0.04). Chronic renal disease was a risk factor for death in the study group. No stroke occurred during the study.ConclusionsEpisodes of paroxysmal AF in patients with systolic heart failure and implanted cardioverter-defibrillator systems are quite common. The majority of the episodes recorded in the study were asymptomatic.
Introduction: Implantable cardioverter defibrillators due to the possibility of continuous recording of intracardiac electrograms can detect episodes of atrial fibrillation. In practice, this allows better identification of patients with asymptomatic AF episodes, thus increasing the proportion of patients who may benefit from pharmacological prophylaxis of thromboembolic events, particularly stroke. Hypothesis: If intracardiac electrogram analysis should be part of each visit carried out in patients with implantable cardioverter defibrillator, how much of detected episodes of atrial fibrillation is asymptomatic. Methods: The study included 174 consecutive outpatient cases with heart failure, sinus rhythm and implanted Cardioverter Defibrillator and Cardiac Resynchronisation Therapy with Defibrillator. Control visits with analysis intracardiac electrograms records occurred every three months. Each AF episode stored in the device’s memory lasting at least 30 seconds was considered an episode of atrial fibrillation. A symptomatic episode was considered when arrhythmia led to ICD shock, heart deterioration, collapse or fainting, palpitations, weakness, chest pain or shortness of breath accompanied by a feeling of irregular heartbeat. During mean follow-up of 20 months, 901 visits were carried out. 147 patients had at least one year of follow-up. Results: Atrial fibrillation (AF) episodes in the study occurred in 54 (31.0%) patients. Of the 241 atrial fibrillation episodes recorded in the device’s memory, 71.4% were asymptomatic. There was no statistically significant difference in the incidence of new episodes of atrial fibrillation (P = 0.384) in the study group with a history of stroke or transient ischemic episodes during follow-up. However, asymptomatic AF episodes were more common in stroke patients (P = 0.0074). In the time of observation in the whole group of patients there were no new strokes and transient ischemic attack. Conclusion: In conclusion, detection of asymptomatic atrial fibrillation episodes based on intracardiac electrocardiogram records is effective method. In the study group, such episodes were up 71.4% of all newly detected AF episodes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.